Kyntra Bio, Inc. — Company profile
United States
Last price 4.65 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 18.83M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Details
| Name | Kyntra Bio, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 34 |
| Founded | 1993 |
| Ceo | Thane Wettig |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US31572Q8814 |
| Cusip | 31572Q881 |
| Cik | 0000921299 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Thane Wettig | Chief Executive Officer and Director |
| David DeLucia | Senior Vice President and Chief Financial Officer |
| John Alden | Corporate Secretary and General Counsel |
| Michelle Simonetti | Head of People and Culture and Executive Director |
| Dr. Carrie Brownstein M.D. | Chief Medical Officer |
| Gaia Vasiliver-Shamis | Director of IR and Communications - LifeSci Advisors |
| Carol Gaddum | Vice President of Product Development |
Contact
| Address | 350 Bay Street, Suite 100 #6009, San Francisco, California 94133, United States |
| Phone | 415 978 1200 |
| Website | https://www.kyntrabio.com |